Pfizer and 23andMe have begun enrolling people in their lupus study. The partners aim to recruit 5,000 people into the study of the genetics of lupus over the next 12 months, in part by asking existing 23andMe customers to participate.
Pfizer is settling class-action litigation brought by patients who claimed the drugmaker did not adequately warn them of possible side effects of drugs they were taking to treat their Parkinson's disease or restless leg syndrome.
Slumping sales for cardiovascular drugs isn't exactly a new phenomenon for Big Pharma, with some of the industry's top drugmakers suffering from recent patent expirations. But a new report shows which CV franchises have been hurt the most.
José-Carlos Gutiérrez-Ramos, Pfizer's prominent head of BioTherapeutics R&D in Cambridge, MA, is leaving the pharma giant and jumping into the booming biotech world, prompting a promotion inside the multibillion-dollar research group.
Controversial genetic testing company 23andMe is finding new ways to stay relevant after the FDA yanked its popular--and once lucrative--direct-to-consumer diagnostic from the market in 2013.
It's the big numbers that tend to make headlines during earnings season: Overall sales, top-selling meds, and, of course, earnings per share. Some closely watched new drugs have a moment in the sun, too. But other launches? Barely a glimpse--if any at all. Here's a roundup of the launch stats that caught our eyes.
Pfizer's Viagra sales may be suffering from generic rivals in Europe. But the brand is still going gangbusters in China, helping to soften the blow.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
No one can pin down Pfizer CEO Ian Read when it comes to whether the company will split up--not publicly, anyway. That word won't come till late next year at least. But repeated questioning from analysts during the company's first-quarter earnings call did yield some facts in the matter.
Hospira has worked itself out from under the warning letters for its pharma manufacturing plants in Rocky Mount and Clayton, NC. That means that Pfizer, which is buying Hospira in a $17 billion deal, will not have that hanging over its head, although the company still has plenty of other regulatory issues with which Pfizer will have to contend.